BioCryst Reports Approval Of ORLADEYO (berotralstat) By National Administration of Drugs, Foods, And Medical Devices (ANMAT) In Argentina
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has announced that its drug ORLADEYO (berotralstat) has been approved by Argentina's National Administration of Drugs, Foods, and Medical Devices (ANMAT). This approval allows for the treatment of hereditary angioedema (HAE) in patients in Argentina.
November 29, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals' ORLADEYO has been approved in Argentina, potentially increasing the company's market reach and revenue from sales of the drug.
The approval of ORLADEYO in Argentina is a significant regulatory milestone for BioCryst Pharmaceuticals, likely leading to increased sales and market penetration in the region. This positive development could boost investor confidence and potentially lead to a short-term uptick in the stock price of $BCRX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100